References
- 1. Rossert J. Goodpasture’s disease. Orphanet encyclopedia; 2002.
- 2. Fisher EG, Lager DJ. Anti-glomerular basement membrane glomerulonephritis: A morphologic study of 80 cases. Am J Pathol 2006; 125: 445-50.
- 3. Kalluri R, Gattone II VH, Nollken ME et al. The α3 chain of type IV collagen induces autoimmune Goodpasture sy. Proc. Natl.Acad. Sci USA. 1994;91:6201-5.
- 4. Persson U, Hertz JM, Carlsson M et al. Patients with Goodpasture’s disease have two normal COL4A3 alleles encoding the NC1 domain of the type IV collagen α3 chain. Nephrol Dial Transplant 2004; 19: 2030-5.
- 5. Panjwani AH, Deoskar RB, Falleiro JJJ et al. Goodpasture Syndrome. MJAFI 2003; 59: 77-9.
- 6. Rowe PA, Mansfield DC, Dutton GN. Ophthalmic features of fourteen cases of Goodpasture sy. Nephron 1994; 68: 52-6.
- 7. Segelmark M, Hellmark T, Wieslander J. The Prognostic Significance in Goodpasture’s Disease of Specificity, Titre and Affinity of Anti-Glomerular-Basement-Membrane Antibodies. Nephron Clin Pract 2003; 94: 59-68.
- 8. Briggs WA, Johnson JP, Teichman S, et al. Antiglomerular basement membrane antibody-mediated glomerulonephritis and Goodpasture’s syndrome. Medicine (Baltimore) 1979 Sep; 58 (5): 348-61.
- 9. Lockwood CM, Pearson TA, Rees AJ, et al. Immunosuppression and plasma-exchange in the treatment of Goodpasture’s syndrome. The Lancet 1976; 307(7942):711-5.
- 10. Levy JB, Turner AN, Rees AJ, et al. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 2001; 134:1033-42.
- 11. Vučković B, Ilić T, Mitić I, et al. Goodpastureov sindrom - prikaz slučaja. Medicinski pregled 2004; 57(7-8):391-5.